Etiology and Pathogenesis of Scleroderma

Kelley's Textbook of Rheumatology: Volume 1-2, Ninth Edition

Volumn 2, Issue , 2012, Pages 1343-1365

  Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929932336     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1738-9.00083-9     Document Type: Chapter

References (118)

1. P Dieudé, C Boileau and Y Allanore (2011) Immunogenetics of systemic sclerosis. Autoimmun Rev 10(5), 282-290
2. FC Arnett, RF Howard, F Tan, et al. (1996) Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Arthritis Rheum 39(8), 1362-1370
3. C Feghali-Bostwick, TA Medsger Jr and TM Wright (2003) Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 48(7), 1956-1963
4. T Frech, D Khanna, B Markewitz, et al. (2010) Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthritis Rheum 62(7), 2109-2116
5. FC Arnett, P Gourh, S Shete, et al. (2010) Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 69(5), 822-827
6. TR Radstake, O Gorlova, B Rueda, et al. (2010) Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet 42(5), 426-429
7. T Muryoi, KN Kasturi, MJ Kafina, et al. (1992) Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 175(4), 1103-1109
8. M Markiewicz, EA Smith, S Rubinchik, et al. (2004) The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin Exp Rheumatol 22(3 Suppl 33), S31-S34
9. JM Tabuenca (1981) Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet 2(8246), 567-568
10. PA Hertzman, WL Blevins, J Mayer, et al. (1990) Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med 322(13), 869-873
11. Y Mori, VM Kahari and J Varga (2002) Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 4(2), 113-122
12. ZD McCormic, SS Khuder, BK Aryal, et al. (2010) Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health 83(7), 763-769
13. J Varga, HR Schumacher and SA Jimenez (1989) Systemic sclerosis after augmentation mammoplasty with silicone implants. Ann Intern Med 111(5), 377-383
14. EC Janowsky, LL Kupper and BS Hulka (2000) Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 342(11), 781-790
15. J Varga, UF Haustein, RH Creech, et al. (1991) Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 265(24), 3292-3295
16. CM Artlett, JB Smith and SA Jimenez (1998) Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338(17), 1186-1191
17. JL Nelson, DE Furst, S Maloney, et al. (1998) Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351(9102), 559-562
18. WA D’Angelo, JF Fries, AT Masi and LE Shulman (1969) Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 46(3), 428-440
19. AJ Freemont, J Hoyland, P Fielding, et al. (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126(6), 561-568
20. RJ Prescott, AJ Freemont, CJ Jones, et al. (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166(3), 255-263
21. JN Fleming, RA Nash, DO McLeod, et al. (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3(1), e1452
22. MB Kahaleh (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 34(8), 978-983
23. SA Yousem (1990) The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 21(5), 467-474
24. MJ Overbeek, MC Vonk, A Boonstra, et al. (2009) Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 34(2), 371-379
25. RA Hawkins, HN Claman, RA Clark and JC Steigerwald (1985) Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 102(2), 182-186
26. D Cox, L Earle, SA Jimenez, et al. (1995) Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. Arthritis Rheum 38(7), 939-945
27. A Jelaska and JH Korn (2000) Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 43(10), 2230-2239
28. F Verrecchia, J Laboureau, O Verola, et al. (2007) Skin involvement in scleroderma—where histological and clinical scores meet. Rheumatology (Oxford) 46(5), 833-841
29. A Rossi, F Sozio, P Sestini, et al. (2010) Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. Hum Pathol 41(3), 366-374
30. CA Davies, M Jeziorska, AJ Freemont and AL Herrick (2006) The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 37(2), 190-197
31. J Varga and RI Bashey (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12(2-4), 187-199
32. AJ van der Slot, AM Zuurmond, AF Bardoel, et al. (2003) Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem 278(42), 40967-40972
33. ML Whitfield, DR Finlay, JI Murray, et al. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100(21), 12319-12324
34. H Gardner, JR Shearstone, R Bandaru, et al. (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 54(6), 1961-1973
35. A Milano, SA Pendergrass, JL Sargent, et al. (2008) Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 3(7), e2696
36. D Bouros, AU Wells, AG Nicholson, et al. (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12), 1581-1586
37. CG Roberts, LK Hummers, WJ Ravich, et al. (2006) A case-controlled study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55(12), 1697-1703
38. J Wipff, Y Allanore, F Soussi, et al. (2005) Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 52(9), 2882-2888
39. ER Fisher and GP Rodnan (1958) Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol 65(1), 29-39
40. DC Trostle, CD Bedetti, VD Steen, et al. (1988) Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 31(3), 393-400
41. WP Follansbee, TR Zerbe and TA Medsger Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1), 194-203
42. F Fernandes, FJ Ramires, E Arteaga, et al. (2003) Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 9(4), 311-317
43. WP Follansbee, TR Zerbe and TA Medsger Jr (1993) Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 125(1), 194-203
44. A Nehra, SJ Hall, G Basile, et al. (1995) Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153(4), 1140-1146
45. HR Schumacher Jr (1973) Joint involvement in progressive systemic sclerosis (scleroderma): a light and electron microscopic study of synovial membrane and fluid. Am J Clin Pathol 60(5), 593-600
46. JH Distler, O Distler, C Beyer and G Schett (2010) Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 62(10), 2831-2844
47. RM Baxter, TP Crowell, ME McCrann, et al. (2005) Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest 85(10), 1199-1209
48. LD Siracusa, R McGrath, Q Ma, et al. (1996) A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6(4), 300-313
49. ER Neptune, PA Frischmeyer, DE Arking, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33(3), 407-411
50. R Lemaire, G Farina, E Kissin, et al. (2004) Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum 50(3), 915-926
51. PJ Christner, J Peters, D Hawkins, et al. (1995) The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum 38(12), 1791-1798
52. S Takagawa, G Lakos, Y Mori, et al. (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of SSc. J Invest Dermatol 121(1), 41-50
53. A Servettaz, C Goulvestre, N Kavian, et al. (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182(9), 5855-5864
54. Y Zhang, LL McCormick, SR Desai, et al. (2002) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168(6), 3088-3098
55. S Sonnylal, CP Denton, B Zheng, et al. (2007) Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56 334-344
56. CP Denton, GE Lindahl, K Khan, et al. (2005) Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor-β receptor (TβRIIδk). J Biol Chem 280(16), 16053-16065
57. G Lakos, S Takagawa and J Varga (2004) Animal models of SSc. Methods Mol Med 102 377-393
58. J Varga and DJ Abraham (2007) paradigm multisystem fibrosing disorder. J Clin Invest 117(3), 557-567. Systemic sclerosis
59. MB Kahaleh, GK Sherer and EC LeRoy (1979) Endothelial injury in scleroderma. J Exp Med 149(6), 1326-1335
60. MM Cerinic, G Valentini, GG Sorano, et al. (2003) Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 32(5), 285-295
61. VS Rajkumar, C Sundberg, DJ Abraham, et al. (1999) Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 42(5), 930-941
62. VS Rajkumar, K Howell, K Csiszar, et al. (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7(5), R1113-1123
63. AD Cambrey, NK Harrison, KE Dawes, et al. (1994) Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 11(4), 439-445
64. M Hebbar, JP Peyrat, L Hornez, et al. (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43(4), 889-893
65. O Distler, JH Distler, A Scheid, et al. (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95(1), 109-116
66. O Distler, A Del Rosso, R Giacomelli, et al. (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4(6), R11
67. M Kuwana, Y Okazaki, H Yasuoka, et al. (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364(9434), 603-610
68. M Kuwana, J Kaburaki, Y Okazaki, et al. (2006) Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 54(6), 1946-1951
69. ND Del Papa, N Quirici, D Soligo, et al. (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54(8), 2605-2615
70. C Beyer, G Schett, S Gay, et al. (2009) Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 11(2), 220
71. JH Distler, A Jüngel, M Pileckyte, et al. (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 56(12), 4203-4215
72. G Zhou, LA Dada, M Wu, et al. (2009) Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol 297(6), L1120-1130
73. C Stockmann, Y Kerdiles, M Nomaksteinsky, et al. (2010) Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci U S A 107(9), 4329-4334
74. A Gabrielli, EV Avvedimento and T Krieg (2009) Scleroderma. N Engl J Med 360(19), 1989-2003
75. S Svegliati, R Cancello, P Sambo, et al. (2005) Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280(43), 36474-36482
76. AD Roumm, TL Whiteside, TA Medsger Jr and GP Rodnan (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27(6), 645-653
77. VM Kahari, M Sandberg, H Kalimo, et al. (1988) Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 90(5), 664-670
78. LI Sakkas, B Xu, CM Artlett, et al. (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168(7), 3649-3659
79. VV Yurovsky, FM Wigley, RA Wise and B White (1996) Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48(1-2), 84-97
80. MR York, T Nagai, AJ Mangini, et al. (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 56(3), 1010-1020
81. S Assassi, MD Mayes, FC Arnett, et al. (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62(2), 589-598
82. H Duan, J Fleming, DK Pritchard, et al. (2008) Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 58(5), 1465-1474
83. G Lakos, D Melichian, M Wu and J Varga (2006) Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73(5), 224-237
84. AO Aliprantis, J Wang, JW Fathman, et al. (2007) Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 104(8), 2827-2830
85. C Mavalia, C Scaletti, P Romagnani, et al. (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151(6), 1751-1758
86. Y Parel, M Aurrand-Lions, A Scheja, et al. (2007) Presence of CD4+ CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 56(10), 3459-3467
87. F Boin, U De Fanis, SJ Bartlett, et al. (2008) T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 58(4), 1165-1174
88. T Matsushita, M Hasegawa, Y Hamaguchi, et al. (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33(2), 275-284
89. TR Radstake, L van Bon, J Broen, et al. (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 4(6), e5903
90. TR Radstake, L van Bon, J Broen, et al. (2009) Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 4(6), e5981
91. L van Bon, C Popa, R Huijbens, et al. (2010) Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 69(8), 1539-1547
92. L Casciola-Rosen, F Wigley and A Rosen (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185(1), 71-79
93. SS Baroni, M Santillo, F Bevilacqua, et al. (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25), 2667-2676
94. J Henault, G Robitaille, JL Senecal and Y Raymond (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54(3), 963-973
95. R Lafyatis, C O’Hara, CA Feghali-Bostwick and E Matteson (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56(9), 3167-3168
96. S Sato, M Hasegawa, M Fujimoto, et al. (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165(11), 6635-6643
97. EC Baechler, FM Batliwalla, G Karypis, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100(5), 2610-2615
98. D Kim, A Peck, D Santer, et al. (2008) Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 58(7), 2163-2173
99. F Ramirez, S Tanaka and G Bou-Gharios (2006) Transcriptional regulation of the human alpha 2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. Matrix Biol 25(6), 365-372
100. AK Ghosh and J Varga (2003) Transcriptional coactivators p300/CBP and type I collagen gene expression. Current Sci 85 155-161
101. J Varga and DJ Abraham (2007) Systemic sclerosis: paradigm multisystem fibrosing disorder. J Clin Invest 117(3), 557-567
102. HY Chang, JT Chi, S Dudoit, et al. (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99 12877-12882
103. R Kalluri and EG Neilson (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12), 1776-1784
104. R Abe, SC Donnelly, T Peng, et al. (2001) Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 166(12), 7556-7562
105. S Bhattacharyya, W Ishida, M Wu, et al. (2009) A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 28(10), 1285-1297
106. JH Distler, A Jüngel, LC Huber, et al. (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56(1), 311-322
107. S Sonnylal, X Shi-Wen, P Leoni, et al. (2010) Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum 62(5), 1523-1532
108. LE Olson and P Soriano (2009) Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell 16(2), 303-313
109. L Klareskog, R Gustafsson, A Scheynius and R Hallgren (1990) Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 33 1534-1541
110. J Wei, D Melichian, J Komura, et al. (2011) Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 63 1707-1717
111. N Kavian, A Servettaz, C Mongaret, et al. (2010) Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 62(11), 3477-3487
112. AM Ferreira, S Takagawa, R Fresco, et al. (2006) Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 126(8), 1900-1908
113. H Yasuoka, E Hsu, XD Ruiz, et al. (2009) The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. Am J Pathol 175(2), 605-615
114. T Oga, T Matsuoka, C Yao, et al. (2009) Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 15(12), 1426-1430
115. AM Tager, P LaCamera, BS Shea, et al. (2008) The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14(1), 45-54
116. P Gasse, C Mary, I Guenon, et al. (2007) IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117(12), 3786-3799
117. J Varga, A Olsen, J Herhal, et al. (1990) Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest 20(5), 487-493
118. J Wei, AK Ghosh, JL Sargent, et al. (2010) PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 5(11), e13778